Neuland Laboratories Q1 Results: Earnings call scheduled for Aug 5
NiveshIQ
NSE: NEULANDLAB · Healthcare
Neuland Laboratories Ltd.
₹19,697.00▲ ₹826.00 (+4.38%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on NEULANDLAB. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Neuland Laboratories Ltd.
Neuland Laboratories Limited is a leading Indian manufacturer of active pharmaceutical ingredients (APIs) with a global presence in India, Europe, the United States, and internationally. The company's core business is driven by the sale of APIs, custom manufacturing solutions, and peptide synthesis services. In FY26, Neuland Laboratories reported a 40% rise in net profit, with revenue standing at ₹606 Cr. The company has a strong competitive position in the Indian pharmaceutical market, with a focus on high-quality products and customer satisfaction. Neuland Laboratories is expected to continue its growth trajectory, driven by increasing demand for APIs and custom manufacturing services. The company's recent attendance at the Nuvama UK Conference and investor meet on June 5 indicate its co
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,559 Cr +130.60% | ₹1,477 Cr -5.30% | ₹2,023 Cr +37.00% |
| EBITDA Margin | 29.63% | 21.87% | 29.89% |
| Net Profit | ₹300.00 Cr +158.60% | ₹261.00 Cr -13.00% | ₹364.00 Cr +39.50% |
| EPS | ₹233.89 | ₹202.74 | ₹283.71 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Neuland Laboratories to declare ₹34 dividend at AGM on Aug 4
Neuland Laboratories to declare ₹34 dividend at AGM on Aug 4
🔒
+ 3 more stories about Neuland Laboratories Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹776 Cr, PAT ₹213 Cr, EPS ₹165.76, EBITDA margin 41.2%. Growth context: PAT YoY -68.1%, revenue QoQ +76.4%, PAT QoQ +418.7%. Street verdict: strong beat, revenue surprise +15.3%, PAT surprise +42.2%.
Management's near-term growth strategy is centered on product launches, approvals, and therapy-mix improvement, which ar...
FY26 (last completed FY): revenue ₹2, 023 Cr, PAT ₹364 Cr, EBITDA margin 29.9%, EPS ₹283.71. Year-on-year: revenue YoY +...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for NEULANDLAB
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track NEULANDLAB alongside your other holdings
Unlock full NEULANDLAB research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Neuland Laboratories Ltd.?
NiveshIQ detects active intelligence signals for Neuland Laboratories Ltd. (NEULANDLAB) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Neuland Laboratories Ltd.?
Neuland Laboratories Ltd. operates in the Healthcare sector with a market capitalisation of ₹2,277,305.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.